Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the highly anticipated national launch of JUVÉDERM® VOLUX™ XC. The long-lasting hyaluronic acid (HA) filler is now available at aesthetic practices for consumers over the age of 21 with moderate to severe loss of jawline definition.1
“With 40% of aesthetically-aware consumers considering treatment in the next year to their jawline or jowls with dermal filler,2* Allergan Aesthetics is excited to address this need by offering JUVÉDERM® VOLUX™ XC, a specifically designed and well-researched solution,” said Carrie Strom, President, Global Allergan Aesthetics and Senior Vice President, AbbVie. “As the category leader, we continue to innovate by providing aesthetic specialists and patients the broadest portfolio of differentiated fillers.”1,3-7
“Many different types of patients can benefit from JUVÉDERM® VOLUX™ XC whether you want to address the appearance of jowls or the contour of the jawline,” said Dr. Sachin Shridharani, board-certified plastic surgeon.1 “With the addition of this new dermal filler to the JUVÉDERM® Collection, I can create a smooth, natural-looking, and long-lasting contour that lasts up to twelve months with optimal treatment.”1
JUVÉDERM® VOLUX™ XC is the newest member of the JUVÉDERM® Collection, and offers a minimally invasive, non-surgical treatment option with minimal downtime.1 In the JUVÉDERM® VOLUX™ XC clinical trial, patients reported high satisfaction with the results of their treatment.1 The JUVÉDERM® Collection is the number one chosen dermal filler collection in the U.S.8† Additionally, in a survey of aesthetic providers with experience using three or more dermal filler brands, the JUVÉDERM® brand was preferred over two times more than other dermal filler brands.9‡
“The shape of the jawline has a profound effect on an individual’s appearance,10 which makes treating this area challenging and requires the practitioner to have advanced skills and precision,” said Dr. David Shafer, double board-certified plastic surgeon and Allergan Medical Institute (AMI) trainer. “With the approval of JUVÉDERM® VOLUX™ XC, the AMI curriculum has expanded to include in-depth training, robust clinical trial data, and resources backed by science to ensure that providers have the proper knowledge and technique required to safely treat appropriate patients to meet their aesthetic goals.”
Commonly reported side effects in the clinical study included tenderness, lumps/bumps, pain, swelling, firmness, bruising, redness, itching, and discoloration at the injection sites, as reported in their 30-day daily diaries.1 These side effects are consistent with HA filler injections and were usually mild (causing little discomfort and no effect on daily activities) or moderate (causing some discomfort and effect on daily activities) in severity.1 Most of these side effects went away on their own within two weeks.1
Consumers and new patients who receive aesthetic treatment from the JUVÉDERM® Collection of Fillers, can also enroll in Allē, the Allergan Aesthetics loyalty rewards program to unlock access to curated content, exclusive offers, and personalized rewards that can be used for savings on the Allergan Aesthetics portfolio of products and redeemed at a participating provider’s office, subject to applicable program terms and conditions. Allē is the first and only loyalty program in the aesthetics market to also offer consumers the ability to earn points on over 40 non-Allergan Aesthetics treatments and brands.
For more information on the JUVÉDERM® Collection of Fillers, visit Juvederm.com and follow @JUVEDERM on Instagram.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.AllerganAesthetics.com.
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.